ArticleFrontiers in oncology2026
Conversion and resection rates in borderline resectable and locally advanced pancreatic cancer following neoadjuvant therapy: a retrospective multicenter cohort study.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant therapy (NAT) may improve resectability and survival in borderline resectable and locally advanced unresectable pancreatic ductal adenocarcinoma (PDAC). However, the outcomes, biomarker utility, and the impact of NAT regimens remain understudied. Methods: Retrospective analysis of PDAC patients (2004-2018) from three tertiary centers in Saudi Arabia. Patients who were deemed unresectable or borderline resectable at initial presentation. Analyzed variables included demographics, tumor characteristics (location, stage), NAC regimens (FOLFIRINOX, GEMCAP, gemcitabine monotherapy), response to therapy (RECIST criteria), surgical outcomes (resection rate, R0 resection), CA19-9 levels, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and survival outcomes (overall survival (OS) and progression-free survival (PFS)). Results: Thirty-nine patients were eligible for the study. Median age was 60 years (range: 29-79 years). The study population mainly consisted of male patients (25/39, 64%). The majority (30/39, 80%) had a good performance status (ECOG PS 0-1). Most patients (30/39, 77%) in the head of pancreas, while the remainder (8/39) had it in the body or tail., Following neoadjuvant chemotherapy, 31% of patients (12/39) had surgical resection. R0 resection was accomplished in 33% of those patients (4/12). Surgery was associated with significantly improved median progression-free survival (PFS) compared to no surgery (19.6 vs 5.8 months; p=0.008). Certain factors, including poorer performance status, elevated CA19-9 levels, high NLR and PLR, and weight loss, were associated with worse PFS and OS in univariate analysis; however, these findings were not statistically significant. Multivariate analysis also suggested numerical differences in PFS and OS based on these factors, but the limited sample size likely prevented statistical significance. Conclusions: NAT facilitates resection in approximately one-third of initially unresectable PDAC cases, with a significant improvement in PFS for patients undergoing subsequent surgery. Elevated pre-treatment CA19-9, NLR, and PLR may identify patients less likely to benefit from NAC. Biomarker-driven trials are warranted to optimize patient selection and personalize treatment strategies, especially in resource-constrained settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.